What Is the Status of the Dupixent Lawsuit in Tennessee?

Super Lawyers® 2014–2024(888) 348-2735

Dupixent — CTCL Litigation

The Dupixent Litigation, Explained

Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.

Marin & Murphy is not licensed in Tennessee; details below.

Partners

Stefanie A. Murphy & Matthew T. Marin

Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.

No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.

Marin & Murphy Law Firm is not licensed in Tennessee; details below.

Where Things Stand in the Dupixent CTCL Litigation

Dupixent (dupilumab), a Sanofi and Regeneron prescription biologic prescribed to patients in Tennessee and nationwide, has been FDA-approved since March 2017 and now carries nine indications, including atopic dermatitis, asthma, and COPD. The order that matters for Tennessee filings came in June 2026: the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. At least 36 identified member cases were on the MDL docket — the same proceeding a case from Tennessee would join — as of September 15, 2026; the MDL 3180 tracker keeps the current count and its method. For Tennessee claimants as for all others, no court has ruled on the merits and no settlement exists.

What the Filings Allege — and What They Do Not

The allegation — in Tennessee as anywhere else — is an association, not an adjudicated fact. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. The Dupixent label dispensed in Tennessee, as everywhere, carries no lymphoma or malignancy warning today. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in Tennessee or anywhere else.

A Tennessee Family’s Dupixent Case in MDL 3180

The earliest-filed case in the litigation comes from Tennessee: Richardson v. Regeneron Pharmaceuticals, Inc., filed in the Middle District of Tennessee on October 1, 2025 (No. 3:25-cv-01125, public docket) by the administrator of her mother’s estate. The complaint alleges that the decedent received Dupixent injections in June and July 2024, developed T-cell lymphoma, and died on October 28, 2024, and it brings wrongful-death and survival claims against Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. The case was listed on Schedule A of the June 4, 2026 transfer order and now proceeds in MDL 3180 in the District of New Jersey. These are allegations from a complaint; no court has ruled on them, and no settlement exists.

Who the Filed Cases Include

People in the consolidated cases — a group any qualifying claimant from Tennessee would join — used Dupixent and received a diagnosis of cutaneous T-cell lymphoma or a related T-cell subtype during or after use. No minimum duration of Dupixent use is required — in Tennessee or anywhere — and the group includes estate claims, brought under state wrongful-death and survival statutes, for patients who have died. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for a Tennessee resident, it is a question for an attorney licensed in Tennessee.

Tennessee’s Federal Courts and the Path to MDL 3180

Tennessee is served by three federal district courts: the United States District Court for the Eastern District of Tennessee; the United States District Court for the Middle District of Tennessee; and the United States District Court for the Western District of Tennessee. No Dupixent CTCL lawsuit filed there proceeds alone — the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a Tennessee case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. The destination is the same consolidated proceeding either way; a claim from Tennessee stays an individual claim, because an MDL is not a class action.

Filing Deadlines Under Tennessee Law

Tennessee’s general statute of limitations for personal-injury claims is one year under Tenn. Code § 28-3-104. Tennessee applies a discovery rule: accrual is deferred until the plaintiff discovers, or through reasonable care and diligence should have discovered, the injury and the identity of the wrongdoer. That one-year period is among the shortest in the country, which makes the timing analysis the first task in any Tennessee claim. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and Tennessee tolling and accrual doctrine. An attorney licensed in Tennessee can evaluate whether a claim is timely.

Tennessee courts generally measure the one-year wrongful-death period from the underlying injury rather than the death itself — an unusually strict rule — and the suit is brought by the surviving spouse or personal representative (Tenn. Code Ann. §§ 20-5-106, 20-5-107).

How Common Is CTCL in Tennessee?

Tennessee is home to about 7.2 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 60 new CTCL diagnoses across Tennessee in a typical year. Because the disease is so rare, no statistic here answers an individual question; in Tennessee, a single claim turns on medical records read against state law.

About Marin & Murphy Law Firm and Tennessee

Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in Tennessee. The firm does not accept Tennessee legal matters; inquiries from Tennessee residents are referred to attorneys licensed in Tennessee. Some matters may be referred to other lawyers. An attorney licensed in Tennessee can evaluate whether a claim is timely and how Tennessee law applies to a particular diagnosis.

Tennessee Dupixent Litigation FAQs